Expertise in
10
conditions

Dr. Paul G. Rubinstein

Hematology
University Of Illinois Chicago Physician Group (Uicpg)
1801 W Taylor St, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
University Of Illinois Chicago Physician Group (Uicpg)
1801 W Taylor St, 
Chicago, IL 

Overview

Paul Rubinstein is a Hematologist practicing medicine in Chicago, Illinois.

Dr. Rubinstein is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Primary Lymphoma of the Brain, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 9 clinical trials. Dr. Rubinstein is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in IL

Hospital Affiliations

University Of Illinois Hospital And Clinics

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 6 Less Insurance Carriers -

Locations

University of Illinois Chicago Physician Group (Uicpg)
1801 W Taylor St, Chicago, IL 60612
Other Locations
John H. Stroger JR. Hospital of Cook County
1901 W Harrison St, Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: June 01, 2026
Intervention Type: Behavioral, Other, Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: January 21, 2026
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Enrollment Status: Terminated
Publish Date: May 11, 2025
Intervention Type: Other, Genetic
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Enrollment Status: Terminated
Publish Date: March 16, 2023
Intervention Type: Other, Genetic
A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
Enrollment Status: Withdrawn
Publish Date: February 14, 2023
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Antiretroviral therapy
Study Phase: Phase 1
View 7 Less Clinical Trials

28 Total Publications

Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Journal: Research square
Published: November 19, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (3.2 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 53 years. Dr. Gordon is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Gordon is currently accepting new patients.

Expertise in
38
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
Expertise in
38
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
Referral may be required
Before you request

Northwestern Medicine Lou And Jean Malnati Brain Tumor Institute

675 N Saint Clair St Ste 20-100, 
Chicago, IL 
 (3.1 miles away)
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rimas Lukas is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 24 years. Dr. Lukas is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy. Dr. Lukas is board certified in American Board Of Psychiatry And Neurology - Neurology (Certified). Dr. Lukas is currently accepting new patients.

Frequently Asked Questions about Dr. Paul G. Rubinstein

How do I make an appointment with Dr. Paul G. Rubinstein?

You can book an appointment with Dr. Paul G. Rubinstein by calling their office at 312-996-5025. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul G. Rubinstein a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul G. Rubinstein is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul G. Rubinstein specialize in?

While Dr. Paul G. Rubinstein is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Primary Lymphoma of the Brain. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Paul G. Rubinstein participate in research or clinical trials?

Yes. Dr. Paul G. Rubinstein has published 28 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Paul G. Rubinstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul G. Rubinstein accept my insurance?

Dr. Paul G. Rubinstein accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 312-996-5025 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rubinstein's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile